Here are three updates on GI companies to note:
Parsippany-Troy Hills, N.J.-based Allergan slashed it executives’ compensation rates from 2015 to 2016. The company reduced President and CEO Brent Saunders’ salary by 80.8 percent from $21.5 million to $4.1 million.
New York City-based Synergy Pharmaceuticals submitted a supplemental New Drug Application for Trulance. The FDA approved the drug for adults with chronic idiopathic constipation in January 2017. The company is now seeking FDA approval for providers to use Trulance to treat irritable bowel syndrome with constipation.
The FDA reported five patients from an overseas hospital tested positive for Klebsiella pneumoniae after providers treated them with the Tokyo-based Olympus TJF-Q180V duodenoscope. Olympus voluntarily recalled the device in January 2016 to replace a mechanism linked to deadly outbreaks around the world. The unspecified hospital replaced their duodenoscopes in October 2016, according to the FDA.
More articles on gastroenterology:
Gastroenterologist Dr. David Novick releasing book — 4 insights
Allergan slashes executive salaries — CEO loses 80%
Patients receiving gastric acid suppressants at increased risk for recurrent C diff infection: 3 study insights
© Copyright ASC COMMUNICATIONS 2017. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.